Navigation Links
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Date:6/10/2008

- Positive Phase II Results of Roche and Ipsen's First Once-Weekly Human

GLP-1 Presented at the American Diabetes Association Meeting -

NUTLEY, N.J., June 10 /PRNewswire/ -- Roche and Ipsen's investigational type 2 diabetes drug taspoglutide (R1583) has been shown to provide significant improvements in glucose control and weight loss after only eight weeks of treatment(1,2) with a safety and tolerability profile that supports entry into Phase III. Taspoglutide, originating from Ipsen's research, is the first human once weekly glucagon-like peptide-1 (GLP-1) analogue. It is a compound similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. Based on these promising Phase II results presented at the American Diabetes Association (ADA) meeting in San Francisco, Roche has made the decision to move taspoglutide into Phase III clinical trials with the program anticipated to start in the second half of 2008.

"These data reinforce the role of GLP-1 in type 2 diabetes and Roche and Ipsen believe taspoglutide has the potential to be a best-in-class treatment," said William M. Burns, CEO, Pharmaceuticals Division of Roche and Jean-Luc Belingard, Chairman and CEO of the Ipsen Group. "GLP-1 analogues, which stimulate insulin secretion and suppress glucagon secretion, are true innovations in the diabetes field. Roche and Ipsen are pleased to move this potentially best-in-class product into phase III trials and look forward to working together to bring it to market," they said.

The Phase II studies showed that the safety profile of taspoglutide supports the move to Phase III with the most common adverse event reported being mild-to-moderate nausea. These events were dose-dependent, and in most cases, resolved spontaneously while continuing on therapy.

"These data show that taspoglutide is a promising once weekly treatment for patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medica
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
2. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Roche responds to announcement of IDEAL hepatitis C trial results
8. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... Ticket Down is a reliable source ... When it comes to the summer concert schedule, it just ... native is one of the biggest names in country music and ... currently out on his “That’s My Kind of Night” tour featuring ... will be making through the rest of the summer and into ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... 31 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... are scheduled to present at the,Canaccord Adams 28th Annual ... p.m. Eastern Time. The Canaccord Adams 28th Annual Global,Growth ... Boston,Massachusetts., To access the webcast, go to the ...
... Call Today at 5:00 p.m. Eastern Time -, ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... progress and financial results,for the second quarter ended ... are to develop picoplatin as an oncology,platform compound ...
... July 31 Mylan Inc. (NYSE: MYL ),today ... stock,issuance, the company has declared its quarterly dividend of ... 6.5% and a liquidation,preference of $1,000.00 per share) payable ... record as of August 1, 2008., Mylan Inc., ...
... PARAMUS, N.J., July 31 Smart Balance Inc.,(Nasdaq: ... marketing organization,today. Richard McWilliams has been named to ... brands, reporting to Gregory Venner, executive,vice president and ... the marketing efforts for the Company,s core brands., ...
... ARBOR, Mich. Pat Phalin learned she had hearing loss ... her local school. The pupils heard sounds she could not ... a pattern in his wife,s family history. Her mother, grandfather ... the Phalins, children had hearing problems before he reached school ...
... ST. LOUIS, July 31 Stereotaxis, Inc. (Nasdaq:,STXS) ... results for the,second quarter ended June 30, 2008, ... The Company will host a conference call and ... Eastern Time to discuss the Company,s,second quarter results ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 7Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 8Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 9Health News:Smart Balance Announces Marketing Organization Appointment 2Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: